Study Description: The purpose of this study is to compare mirvetuximab soravtansine (IMGN853), an experimental drug made by ImmunoGen, Inc. (the Sponsor of this clinical trial) to standard therapy. Also, this study seeks to find out what effects, both good and/or bad, the study drug may have on the patient and their type of cancer. Another purpose of this study is for researchers to learn if a biomarker test for folate receptor alpha (FRa) protein is helpful in determining which patients are most likely to benefit from mirvetuximab soravtansine.
Principal Investigator: Sharad Ghamande
Eligibility Criteria: INCLUSION CRITERIA Patients must have one of the following pathologically documented, definitively diagnosed tumor types: Advanced Epithelial Ovarin Cancer, primary peritoneal cancer, fallopian tube cancer Must be at least 18 years of age or older
Compensation: No, subjects will not be compensated.
If you don't see specific studies that interest you, please submit your contact information for future studies.